戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 nopathy, monoclonal plasma cell disorder and skin changes).
2 % as the relative humidity of the underlying skin changed.
3 opathy, monoclonal plasma cell neoplasm, and skin changes.
4 aly, endocrinopathy, monoclonal protein, and skin changes.
5 rm mass in the left flank with no associated skin changes.
6 eripheral edema, ascites, or effusions), and skin changes.
7 no significant weight loss, diarrhea or GVHD skin changes.
8 f scratching activity and scratching-induced skin changes.
9 ays, 2 new employees presented with the same skin changes.
10    Initially 16 employees developed pruritic skin changes.
11 lerosis including 5 overarching domains: (1) skin changes, (2) symptoms, (3) emotional and social fun
12 ; 16), scarring (66%; 23), and other chronic skin changes (40%; 14).
13  facial feature, muscles tone abnormalities, skin changes and breathing difficulties.
14 e relatively rapid and steady improvement of skin changes and knee joint contractures in patients wit
15 ars of Rag1-/- mice, IL-23 initially induced skin changes and levels of Il22 mRNA that were indisting
16  duration, affected the relationship between skin changes and symptoms and downstream functioning and
17 f importance grouped within 5 HRQOL domains: skin changes and symptoms, social functioning, psycholog
18 as observed between the intensity of trophic skin changes and the pulsatility index.
19 itive; 25.7% (9 patient) reported no chronic skin changes, and 5.7% (2 patients) reported never havin
20 isual acuity, clinically observable tattooed skin changes, and biopsy results.
21 junctivitis, meibomitis, dry eye, periocular skin changes, and trichomegaly.
22 er extremity symptoms including edema, pain, skin changes, and, in advanced cases, ulceration.
23 re performed in most individuals, noticeable skin changes are observed approximately 1 month after a
24 were minimal; there were small or no adverse skin changes at the maximum effective myotoxic doses.
25                                              Skin changes caused by ionizing radiation have been scie
26 nimal skin changes or the absence of visible skin changes during reactions to light, including lack o
27 isorder (PCD), organomegaly, endocrinopathy, skin changes, edema, sclerotic bone lesions, and thrombo
28 ed according to CTCAE version as G1 (minimal skin changes, faint erythema, or dry desquamation) or G2
29             Most of these hyperproliferative skin changes improve when a MEK inhibitor is co-administ
30            To analyze the causative agent of skin changes in employees of a company that produced her
31  administration of benzoyl peroxide produces skin changes in the hairless mouse that qualitatively re
32 ce overexpressing ornithine decarboxylase in skin, changes in tissue polyamine levels, particularly p
33 od monocytes reduces DC accumulation and the skin changes induced either by injecting IL-23 or by app
34 support the hypothesis that inflammation and skin changes involving activin A cause some sensory neur
35 galy, Endocrinopathy, Monoclonal protein and Skin changes) is a paraneoplastic disorder with a 'demye
36 ltiple endocrinopathies, monoclonal protein, skin changes) is a rare disease associated with a plasma
37 s with anti-Th/To antibodies had more subtle skin changes, less severe vascular involvement, and less
38 ical contribution of ACT1 to proinflammatory skin changes mediated by the IL-23/IL-17 signaling axis
39 distinguish those patients with the hallmark skin changes of DM and no clinical evidence of muscle di
40 pus erythematosus, dermatomyositis), and the skin changes of potentially fatal disorders such as graf
41             None of the patients had obvious skin changes or cardiovascular disease atypical for thei
42                                      Minimal skin changes or the absence of visible skin changes duri
43 , endocrinopathy, monoclonal gammopathy, and skin changes (POEMS) syndrome is a rare multisystem dise
44 megaly Endocrinopathy Monoclonal-protein and Skin Changes (POEMS) syndrome.
45 crinopathy, monoclonal plasma cell disorder, skin changes (POEMS)-associated MCD (POEMS-MCD).
46 edis artery decreased with increased trophic skin changes (r=-0.431, P=0.009).
47                                      Because skin changes recurred after discontinuation of imatinib
48 hin weeks of stopping imatinib mesylate, the skin changes recurred in each patient.
49  hardness, pain, oversensitivity, edema, and skin changes reduced over time ( P < .001 for each), whe
50 organomegaly, endocrinopathy, M protein, and skin changes) remains poorly understood.
51                                          The skin changes resolved in all patients, with a faster res
52 ulation by autoantibodies contributes to the skin changes seen in autoimmune thyroid disease.
53                              No inflammatory skin changes such as erythema, swelling, or non-purulent
54 ng syndrome characteristically presents with skin changes such as facial plethora, easy bruising, and
55 elated lymphedema (BCRL) is characterized by skin changes, swelling, fibrosis, and recurrent skin inf
56 , endocrinopathy, monoclonal gammopathy, and skin changes) syndrome is a rare plasma cell disorder ch
57 o rejection, manifesting pathologically with skin changes that form the basis of the Banff 2007 class
58 logy from other inflammatory myopathies with skin changes that have prominent perimysial connective t
59                        This review discusses skin changes that may suggest a psychological problem an
60 ix postwounding that is similar to unwounded skin-changes that correlate with long-term improvement i
61 ciated with only mild side effects including skin changes, transient headache, hyperlipidemia, transa
62 itch signals to the CNS and for the dramatic skin changes triggered by dry-skin-evoked itch and scrat
63 milar to pseudoxanthoma elasticum (PXE), the skin changes were found to be due to amyloid deposition
64 to those already existing in the literature, skin changes were more marked in animals exposed to gado
65 her and aunt, also manifesting with PXE-like skin changes, were heterozygous carriers of a missense m
66 tant mice were protected from psoriasis-like skin changes, which identified a role for Sox13-dependen
67 mean time of 32 d; G3 skin reactions (severe skin changes without pain) were present in 16 lesions, l